Chinese police have detained four top executives of British drug firm GlaxoSmithKline (GSK) in China for alleged bribery and other offenses, state media said yesterday.
Four managers whose responsibilities included operations, human resources, legal affairs and business development had committed “serious” economic crimes, Xinhua news agency said.
The Beijing News newspaper said in a separate report that more than 20 people, including the four executives, were being held in connection with the investigation, which came to light earlier this month.
Others were pharmaceutical and travel industry officials, it said, with at least four travel agencies involved.
Chinese authorities said last week that GSK staff had bribed government officials, pharmaceutical industry groups, hospitals and doctors to help sales of their products and increase prices for drugs.
The bribes were given directly or made through travel agencies and project sponsorship, China’s Ministry of Public Security said on Thursday last week.
It is common practice in China for pharmaceutical firms to offer doctors and hospitals bribes to have their products used, industry insiders say.
At the same time, GSK executives took kickbacks from travel agencies for helping to organize conferences, said the ministry, which is in charge of China’s police.
At least one GSK executive also allegedly received sexual services, in what Chinese law calls “sexual bribery,” the Beijing News said.
A China-based spokeswoman for GSK declined to comment yesterday, while a Singapore-based spokesman did not immediately respond to request for comment.
Last week, the company said in a statement that it had found “no evidence of bribery or corruption of doctors or government officials” in China.
GSK is one of the largest multinational pharmaceutical companies in China with total investment of more than US$500 million, according to its Web site.